JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES) ›› 2015, Vol. 53 ›› Issue (11): 46-49.doi: 10.6040/j.issn.1671-7554.0.2015.531

• Clinical Medicine • Previous Articles     Next Articles

Clinical efficacy of atorvastatincalcium combined with ezetimibe in the treatment of coronary atherosclerosis with hyperlipidemia

RONG Chunli, YAO Wenjing, YANG Qian, LI Ruyi, CAO Dongping, LIU Meixia, PENG Yingxin   

  1. Center of Heart, Hebei General Hospital, Shijiazhuang 050051, Hebei, China
  • Received:2015-06-01 Online:2015-11-10 Published:2015-11-10

PDF (PC)

260

Abstract: Objective To investigate the clinical efficiency and safety of atorvastatincalcium combined with ezetimibe for treating coronary atherosclerosis with hyperlipidemia. Methods A total of 82 cases of coronary atherosclerosis with hyperlipidemia treated in our hospital during May 2013 to Feb. 2014 were collected and divided into two groups. Patients in single drug group (n=41) were treated with atorvastatincalcium only, while patients in the combined drug group (n=41) received atorvastatincalcium and ezetimibe. After 12 weeks, lipid contents of the two groups were compared. Results Before the treatment, the values of TC, TG, HDL-C, LDL-C, and CRP in the two groups were not significantly different (P>0.05). After the treatment, the values of TC, TG, LDL-C, CRP in the two groups were markedly reduced and HDL-C was remarkably increased than before (P<0.05), and the improvement was greater in the combined drug group (P<0.05). The standard rate of LDL-C was 78.05% in combined drug group, which was notably higher than that of the single drug group (53.66%) (P<0.05). There were no differences in liver and renal function between the two groups before and after treatment (P>0.05). Conclusion Atorvastatincalcium combined with ezetimibe has significant lipid-lowering effect in treating coronary atherosclerosis with hyperlipidemia, and does not increase the burden on liver and kidney.

Key words: Coronary atherosclerosis, Hyperlipidemia, Atorvastatincalcium, Ezetimibe, Lipid-lowering effect

CLC Number: 

  • R574
[1] Kaptoge S, Di Angelantonio E, Lowe G, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis[J]. Lancet, 2010, 375(9709): 132-140.
[2] Cleeman JI. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adults treatment panel III)[J]. JAMA, 2001, 285(19): 2486-2497.
[3] 中国成人血脂异常防治指南制定联合委员会. 中国成人血脂异常防治指南[J]. 中华心血管病杂志, 2007, 35(5): 390-419. Joint committee for developing Chinese guidelines on prevention and treatment of dyslipidemia in adults. Chinese guidelines on prevention and treatment of dyslipidemia in adults[J]. Chinese Journal of Cardiology, 2007, 35(5):390-419.
[4] Tikkanen MJ, Fayyad R, Faergeman O, et al. Effect of intensive lipid lowering with atorvascular outcomes in coronary heart disease patients with baseline elevations in alanine aminotransferase levels[J]. Eur Heart J, 2013, 34(1): 679-683.
[5] 李毅亭, 龙明智. 强化他汀治疗对急性冠脉综合征患者炎症因子和预后的影响[J]. 南京医科大学学报: 自然科学版, 2009, 10: 1423-1426. LI Yiting, LONG Mingzhi. Effects of intensive statin therapy on inflammatory factors and prognosis in patients with acute coronary syndrome[J]. Acta Universitatis Medicinalis Nanjing:Natural Science, 2009, 10: 1423-1426.
[6] Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes[J]. N Engl J Med, 2004, 350(15): 1495-1504.
[7] 王艳丽, 于晓原, 张璐璐, 等. 阿托伐他汀钙治疗老年冠心病合并高脂血症的疗效观察[J]. 西北药学杂志, 2013, 1(6) :630-631. WANG Yanli, YU Xiaoyuan, ZHANG Lulu, et al. Clinical effect of atorvastatin calcium in the treatment of elder patients with coronary heart disease complicated with hyperlipidemia[J]. Northwest Pharmaceutical Journal, 2013, 1(6): 630-631.
[8] Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome[J]. N Engl J Med, 2012, 366(1): 9-19.
[9] 陈莉, 王勇. 稳定型冠心病患者的强化他汀治疗[J]. 中国全科医学, 2012, 15(14): 1557-1559. CHEN Li, WANG Yong. Intensive statin therapy in patients with stable coronary artery disease[J]. Chinese General Practice, 2012, 15(14): 1557-1559.
[10] 王一楠. 阿托伐他汀联合非诺贝特治疗老年混合型高脂血症临床疗效观察[J]. 中国心血管病研究, 2011, 9(10): 765-768.
[11] Bays HE, Neff D, Tomassini JE, et al. Ezetimibe: cholesterol lowing and beyond[J]. Expert Rev Cardiovasc Ther, 2008, 6(4): 447-470.
[12] 张茗, 任祝军, 赵丽芬,等. 依折麦布联合小剂量普伐他汀治疗高胆固醇血症疗效观察[J]. 河北医药, 2013, 35(15): 2301-2302.
[13] 童程程, 唐海沁, 李瑾. 依折麦布联合辛伐他汀降脂疗效和安全性的Meta分析[J]. 中国循证心血管医学杂志, 2013, 5(2): 116-120. TONG Chengcheng, TANG Haiqin, LI Jin. A Meta-analysis on lipid-lowering effect and safety of ezetimibe combining simvatatin therapy[J]. Chinese Journal of Evidence-Based Cardiovascular Medicine, 2013, 5(2): 116-120.
[14] Dujovne CA, Ettinger MP, McNeer JF, et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia[J]. Am J Cardiol, 2002, 90(10): 1092-1097.
[15] 毕磊, 曹丹阳, 王伟, 等. 依折麦布联合辛伐他汀在冠心病高脂血症患者中降脂疗效及安全性观察[J]. 中国循证心血管医学杂志, 2014, 6(4): 422-423. BI Lei, CAO Danyang, WANG Wei, et al. Lipid-lowering efficacy and safety of ezetimibe combining simvastatin in patients with coronary heart disease and hyperlipidemia[J]. Chinese Journal of Evidence-Based Cardiovascular Medicine, 2014, 6(4): 422-423.
[1] ZHANG Guang, WANG Guangyin, WU Hongyan, ZHANG Hongyu, WANG Tingting, LI Jiqing, LI Min, KANG Fengling, LIU Yanxun, XUE Fuzhong. A prediction model of hyperlipidemia risk based on the health management population [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(6): 72-76.
[2] WEI Ying, SUN Yawen, GAO Youmei, XUE Fuzhong, YU Hongxia, ZHANG Chengqi. Relationships of dietary patterns with overweight, hypertension, hyperglycemia and hyperlipidemia in career women in Jinan [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(8): 102-107.
[3] LIU Yan-jun, GONG Hui-ping, DU Yi-meng, WANG Xin, DONG Zhao-qiang, LU Qing-hua. Relationship between human protection of telomeres 1 and coronary atherosclerosis [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(10): 58-61.
[4] ZHANG Min1，2, XU Gui-fa1. Effect of nonpharmacotherapy in decreasing the levels of serum lipid in simple hyperlipidemia patients [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2010, 48(8): 117-119.
[5] . Role of apolipoprotein E gene polymorphism and plasma lipids in mild cognitive impairment [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2009, 47(11): 103-107.
[6] LI Jianzhong, ZHAO Jun, GUO Guangqing， CHEN Qi, LIU Jinxia, ZHANG Yanguo
. Apolipoprotein E gene expression in peripheral blood monocyte and lipid analysis of hypertension patients [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2009, 47(02): 50-52.
[7] WU Mao-hong,WANG Feng-yun,SUN Lei,DONG Ming,REN Jian-min. Relationship between post-prandial hyperlipidemia and carotid ather oscerosis and blood rheology in type 2 diabetic patients [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2007, 45(5): 503-507.
[8] LIU Xiang-ju,GAO Hai-qing,BI Yi,SHEN Lin,YOU Bei-an. Grape seed proanthocyanidin extract combined with atorvastatin in prevention of atherosclerosis in rabbits [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2007, 45(11): 1131-1134.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd